Humira RA labeling expansion
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abbott's Humira (adalimumab) label was updated to reflect new data that the monoclonal antibody inhibits irreversible joint damage in patients with rheumatoid arthritis for up to five years. A five-year study conducted in patients with long-standing RA demonstrated that roughly 60 percents of patients showed no radiographic progression after five years. Patients with inadequate response to methotrexate received adalimumab plus methotrexate to evaluate radiographic disease progression and safety of the therapy...
You may also be interested in...
While Opening Dietary Ingredient Portfolio Wider, DuPont Opens Door On Online Supply Store
In its “robust, holistic hub” online, firms in the VMS product supply chain can determine their needs, “by product, solution or delivery formats,” and use a “comprehensive and unique portfolio” to “turn natural sources into shelf-ready products.”
Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: